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THERAVECTYS, a spin off the Pasteur Institute, develops
a new generation of prophylactic and therapeutic vaccines
using optimized lentiviral vectors. It’s most advanced pro-
duct, a therapeutic anti-HIV vaccine treatment, has
entered clinical Phase I/II end of 2012. This vaccination
should allow seropositive patients to gain an immunologi-
cal status identical to the so-called “Functional Cured”
patients who develop an efficient immunological response
capable of controlling the infection without therapy.
Vaccine candidates are integrative and self-inactivated
live-recombinant lentiviral vectors. They encode an HIV
antigen, under the regulation of a patented promoter that
is preferentially induced in APC (generating the specific
immune response), and showing a basal level expression
in all cells (allowing their elimination by the settled
immune response).These vaccine candidates are classified
as “Live recombinant vectored vaccines” (EMA, 2011).
Preclinical studies demonstrated i)the generation of a
strong, specific and very long lasting T-cell immune
response (up to 2 years in murine animal models), ii) the
restricted diffusion of the vaccine candidates after injection
and iii)their fast disappearance within few weeks, corre-
lated with an absence of macroscopic and microscopic
toxicity.
These data allowed the settlement of the anti-HIV
therapeutic Phase I/II clinical trial that is held in France
and Belgium and that has ended the enrollment of the
36 HIV-1 infected patients. THERAVECTYS’ anti-HIV
vaccine treatment is assessed at three doses and safety,
tolerability and immunogenicity compared to a placebo
group. Furthermore, vaccine efficiency is be evaluated
by the interruption of the HAART treatment in all
patients, including placebo. Final results are expected by
2014 with intermediary analysis in April 2014.
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